Work

Biological and surgical determinants in the treatment of rectal cancer

Year: 2022
Type: dissertation
Abstract: Rectal cancer (RC) is a very complex disease that has been increasing in younger patients, imposing a great impact in quality of life. It is an extremely heterogeneous pathology in what regards to behaviour, which is dependent of many factors that determine its course and response to treatment. In the past decades, significant progress has been made in the management of RC due to a better knowledge of disease pathophysiology and consequent development of new therapeutic options. Synchronously with the technical evolution, the concept of oncological treatment also changed, from a perspective exclusively focused on survival outcomes to a model involving concerns with functional results and quality of life. Emphasis changed to minimizing the deleterious effects of treatment. However, many rectal cancer patients are still submitted to medical therapies and surgical options without any benefit and that even add unjustified morbidity. This is the core question of this work: can we find biological and surgical determinants of RC treatment in order to decrease its related morbidity while achieving the intended outcomes? There are biological factors that influence clinical results and there is an undeniable impact of the surgical options we select. As our goal is obtaining the best possible outcomes minimizing morbidity, we must search for the biological and surgical determinants guidelining the optimal treatment. The aim of this project is to provide new insights to possible determinants of RC treatment. We ask the following questions: 1) can we better select patients for chemoradiotherapy through the identification of molecular predictors of response?, 2) can we individualize the surgical technique for each RC patient, using transanal total mesorectal excision or local excision in selected cases? and 3) can we improve assortment of patients for a derivative ileostomy identifying factors predictive of related morbidity? Neoadjuvant therapy is currently given to the majority of locally advanced rectal cancer with a majority of good tumour response. However, one third of patients that undergo chemoradiotherapy do not profit from this option, are at increased risk of disease progression and even unnecessary toxicity. So far, there are no validated predictors of response to chemoradiotherapy to aid in deciding whether the patient should or not undergo this therapy, avoiding related morbidity. Considering their role in rectal cancer oncogenesis and involvement in the response to medical therapies, we hypothesized that microRNAs (miRNAs or miRs), in particular microRNA-16, microRNA-21, microRNA-135b, microRNA-145 and microRNA-335 are biomarkers of response to neoadjuvant CRT, predicting good and bad responders. We found a statistically significant association of microRNA-21 overexpression in pre- chemoradiotherapy rectal cancer tissue and worse response. Our results suggest that microRNA-21 may, indeed, be a biomarker of pathological response in rectal cancer. Confirmation as such could translate into clinical application through the inclusion of the levels of microRNA-21 in algorithms of treatment decision, certainly allowing a better selection of candidates for chemoradiotherapy During the last 30 years, great surgical progress was introduced in RC treatment aiming to improve outcomes and diminishing the morbidity associated with treatment. The most recent of theses attempts is transanal total mesorectal excision, developed in 2010, which yielded very positive short-term results. However, long-term outcomes are still controversial and not clarified. We analysed the oncological outcomes of the learning curve of this technique at our institution and compared them to a matched cohort of patients submitted to the standard of care laparoscopic total mesorectal excision. Similar long-term results regarding local recurrence, overall survival and disease-free survival were found. These results point out to the fact that transanal total mesorectal excision can produce short and long-term oncological safe results, compatible to what has been published for the laparoscopic approach. However, this work also emphasized the demanding learning curve and significant risk for morbidity associated with this novel technique. The fact is that, whatever option is used to performed distal RC surgery, it requires advanced surgical skills and optimal results can only be achieved with adequate training and continuous evaluation of outcomes to ensure they improve as experience grows. Transanal total mesorectal excision does not intent to replace other established approaches to rectal surgery but to add new alternatives to address difficult cases. As we understand TME as one of the greatest revolutions of rectal cancer treatment we also acknowledge its negative impact on the quality of life of patients with distal tumours. In this setting, less aggressive therapeutic strategies started to be discussed in order to decrease therapeutic morbidity, namely neoadjuvant chemoradiotherapy combined with local excision. Through a systematic review and meta analysis that compared the outcomes of local excision and radical surgery in the post neoadjuvant setting, we found similar outcomes between groups in relation to local recurrence, overall survival and disease-free survival. These results are explained by the fact that the most relevant determinant of local recurrence and survival is not the baseline staging but the post chemoradiotherapy one, that reflects tumour biologic behaviour. However, some studies included in this metanalysis were based on initial staging. In sum, after CRT, patients with an incomplete response contained in the mucosa or submucosa with negative nodes (ycT1N0) may be an indication for LE. This strategy can also be considered in trial setting or as an option for patients refusing abdominoperineal resection or with significant comorbidity. Still in rectal cancer surgery, defunctioning ileostomy is frequently constructed to reduce the poor consequences of a leak. However, the majority of patients does not face anastomotic breakdown and is unnecessarily exposed to stoma potential complications. In fact, stoma protective effect needs to be balanced against its morbidity, which is actually quite high. We identified Diabetes Mellitus and complications of the index rectal surgery as predictive of higher ileostomy morbidity and of closure-related problems as well as lower ileostomy reversal. So, when deciding over diverting a colorectal or coloanal anastomosis, the influence of these predictive factors must be taken into account. It is essential to individualize treatment decisions and adopt a more selective approach concerning the use of a defunctioning ileostomy, especially for patients in which the risks of having a stoma may offset potential advantages. In summary, there are many factors influencing the proper therapeutic conduct to follow in the approach of rectal cancer. There are biological and surgical determinants of the treatment of this disease that need to be analysed, in order to achieve the best results with the lowest morbidity. The role of the microRNA in oncogenic pathways is undeniable as is the influence of specific microRNA, namely miR-21, in the response to chemoradiotherapy. Likewise, the choice of particular surgical interventions in different clinical settings can be critical to obtain the appropriate outcomes. We can individualize surgical options through the selective use of transanal total mesorectal excision in distal tumours or local excision in high risk patients with very good response, confined to the submucosa, in post neoadjuvant treatment. Likewise, prior to performing radical surgery, it is imperative to optimize patients and control modifiable risk factors as diabetes mellitus in order to decrease stoma-related morbidity.
Language: Portuguese
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7027118780
Cites: 574
Cited by:
Related to: 10